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Abstract: 
RNA interference (RNAi) is a powerful technology with huge applications for functional genomics, target identification in 
drug discovery and elucidation of molecular signaling pathways. Current RNAi studies have demonstrated the clinical 
potential of small interfering RNAs (siRNAs) in metabolic diseases, cancer, AIDS, malaria, neurodegenerative disorders, 
dental diseases and other illnesses. Interestingly, recent studies have shown that the small RNA molecules, either 
indigenously produced as microRNAs (miRNAs) or exogenously administered synthetic dsRNAs could effectively activate 
a particular gene in a sequence specific manner instead of silencing it. This novel, but still uncharacterized, phenomenon has 
been termed as RNA activation (RNAa). The paradoxical concept of Yin and Yang, which describe two primal opposing but 
complementary principles, can potentially be applied to elucidate the complex phenomenon of RNAa/RNAi in the RNAome. 
This warrants a proper understanding of the RNAi/RNAa molecular pathways in living organisms before any of the small 
dsRNAs can potentially be exploited for therapeutics in human beings.  
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Background: 
RNA interference (RNAi) is a precise and powerful gene 
knock down mechanism conserved in evolution from 
Caenorhabditis elegans to higher mammals. It was first 
experimentally shown in C. elegans and identified that 21- 
to 25-nucleotide short interfering RNAs (siRNAs) are the 
key factors of RNAi [1, 2]. This pioneering experimental 
finding of RNAi phenomenon in C. elegans by Fire et al 
was duly recognized and they were awarded with Nobel 
Prize for Physiology or Medicine in 2006 [3].  This gene 
knock down phenomenon was subsequently observed and 
experimentally proved in flies [4, 5. 6], and vertebrates [7, 
8]. siRNAs theoretically represent ideal drugs for the 
specific inhibition of unwanted or pathogenic gene 
products. The market for RNAi-based drugs as a whole 
could be enormous. There is no disease that affects humans 
that doesn't have a genetic component, and RNAi 
sequences can be tailored to block just about any gene [9]. 
They make it possible by binding and then degrading the 
mRNA produced by the gene before that mRNA can start 
producing a harmful protein, which actually causes the 
illness. And this makes the RNAi a powerful tool with 
enormous applications for functional genomics, druggable 
molecular target identification and elucidation of molecular 
signaling pathways, which might possibly leads to drug 
discovery, and the development of therapies for various 
human diseases/disorders in the near future [5, 10, 11]. So 
far, more than 11000 articles and 1200 reviews were 
already published on RNAi and related fields (as cited in 
the pubmed in December 2007).  
 
Yin and Yang of RNAome 
An improved understanding of RNAi has provided novel 
tools for conducting functional studies in a gene-specific 
approach. So far, RNAi has been used to generate model 
systems, to identify novel molecular targets, to study gene 
function in a genome-wide manner, and to create a new 
niche for clinical therapeutics [12-14]. We and others have 
recently reviewed the therapeutic potential of synthetic 
siRNAs in various human diseases and disorders [10, 12-
14]. We have enlisted the potential siRNA targets for 
treating viral, neurodegenerative, cancer and other diseases 
[10]. The RNAi mechanism [10] can be exploited to knock 
down crucial disease gene or multiple disease genes, 
downstream signaling molecules capable of modulating a 
particular disease, and dominant genes which can lead to a 
genetic disease/ disorder [10]. 
 
Some proof of concept experiments have precisely 
demonstrated that the siRNA efficiency/efficacy largely 
depends on multiple factors (not based on any single factor), 
such as the thermodynamic stability of the duplex at the 5' 
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complex (reduces the silencing ability), GC content, base 
preference for an Adenosine not cytosine at 19
th or
 20
th base 
position of the sense strand (required for 
unwinding/activation step in the RISC), uridine is preferred 
at position 10, adenosine is preferred at position 3 and any 
base at positon 13 except guanosine. These factors are 
thought to play a role in the gene silencing ability of 
synthetic siRNAs and make the designing of siRNAs a 
complex and strenuous process [15-17]. Recently, Hong et 
al (2005) tested the expression inhibition of transgene of 
HBV surface antigen by different amounts of siRNA in the 
presence or absence of mouse orthologue of enhanced RNA 
interference-1 (eri-1).  Dose-response analyses carried out 
in vitro and in vivo using Escherichia-coli-expressed and 
enzyme-digested siRNA (esiRNA) confirmed the dose 
dependent effect. However, the results revealed an 
unexpected decrease of inhibition effect that was associated 
with the introduction of higher dose of esiHBVP, compared 
with lower dose of esiHBVP. They concluded that RNAi 
machinery may be under negative regulation through the 
induction of a series of genes coding for destabilizing 
enzymes by siRNAs introduced into the cell [18]. 
 
 
Figure 1: RNAa/RNAi constitutes the Yin and Yang of the RNAome. The dual concepts of yin and yang which describe 
two primal opposing but complementary principles or cosmic forces said to be found in all non-static objects and processes 
in the universe. This paradoxical concept can potentially be applied to elucidate the complex phenomenon of RNAa/RNAi 
molecular pathways in the RNAome.  
 
By targeting the promoter region of various genes, Li et al 
(2006) have identified several dsRNAs that induce gene 
transcription in a sequence-specific manner. This RNA 
mediated process requires the Argonaute 2 (Ago2) protein 
and is associated with histone changes linked to gene 
activation. Although the exact mechanism is unknown at 
present, the identification of RNA activation (RNAa) may 
still have significant therapeutic application [19]. RNAa 
could potentially be complementing the RNAi according to 
the Yin and Yang Philosophy (Figure 1). The use of RNAi 
is currently being proposed as a gene-specific approach for 
molecular medicine [10, 11]. By the same principle, the 
specific activation of silenced tumor suppressor genes such 
as  p21 or other common dysregulated genes, such as  E-
cadherin, by RNAa may  further add to the growing 
therapeutic prospective of dsRNAs-based drugs in the 
treatment of cancer and other diseases. Interestingly, RNAi 
typically silences genes for 5 to 7 days, but RNAa boosted 
gene activity for up to 13 days [20]. It is not well 
characterized that how small dsRNAs could turn genes ON, 
especially for a very long period. This information also 
indicates a new obstacle for RNAi in which siRNAs may 
undesirably stimulate the expression of off target genes. 
 
Conclusion: 
The molecular machinery of RNAome, involves both 
RNAi/RNAa, still needs to be characterized to further 
explain the question of how the same enzymes of RNAi 
pathway can sometimes turn genes OFF, and sometimes 
ON. Hence, a thorough understanding of the molecular 
machinery of RNAa and RNAi should be required before 
exploiting the RNA interference/activation strategies in 
human beings for therapeutic purposes. 
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